Jane Street Group LLC Raises Stock Position in Veru Inc. (NASDAQ:VERU)

Jane Street Group LLC increased its position in shares of Veru Inc. (NASDAQ:VERU) by 35.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,406 shares of the company’s stock after acquiring an additional 33,952 shares during the quarter. Jane Street Group LLC owned about 0.09% of Veru worth $85,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Wells Fargo & Company MN grew its holdings in Veru by 37.1% in the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock worth $49,000 after purchasing an additional 20,430 shares during the last quarter. Integrated Wealth Concepts LLC grew its stake in Veru by 31.3% during the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company’s stock worth $56,000 after buying an additional 20,500 shares during the last quarter. Gladstone Institutional Advisory LLC grew its stake in Veru by 52.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 86,876 shares of the company’s stock worth $57,000 after buying an additional 30,000 shares during the last quarter. NewEdge Advisors LLC increased its position in Veru by 2,500.0% during the 4th quarter. NewEdge Advisors LLC now owns 130,000 shares of the company’s stock valued at $85,000 after buying an additional 125,000 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Veru by 132.4% in the fourth quarter. SG Americas Securities LLC now owns 153,656 shares of the company’s stock valued at $100,000 after buying an additional 87,528 shares during the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Veru Stock Performance

Shares of NASDAQ VERU opened at $0.62 on Monday. Veru Inc. has a fifty-two week low of $0.45 and a fifty-two week high of $1.42. The company has a market cap of $90.59 million, a PE ratio of -2.38 and a beta of -0.80. The business has a 50-day simple moving average of $0.54 and a two-hundred day simple moving average of $0.61.

Veru (NASDAQ:VERU) last released its earnings results on Thursday, May 8th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. On average, sell-side analysts predict that Veru Inc. will post -0.22 earnings per share for the current fiscal year.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.